Related references
Note: Only part of the references are listed.Dabigatran Etexilate A Review of its Use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
Karly P. Garnock-Jones
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2011)
Novel Oral Anticoagulants in Development: Dabigatran, Rivaroxaban, and Apixaban
Maryam Sattari et al.
AMERICAN JOURNAL OF THERAPEUTICS (2011)
Apixaban in Patients with Atrial Fibrillation
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial (vol 9, pg 1157, 2010)
H. C. Diener et al.
LANCET NEUROLOGY (2011)
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)
Christian T. Ruff et al.
AMERICAN HEART JOURNAL (2010)
Dabigatran and Warfarin in Vitamin K Antagonist-Naive and -Experienced Cohorts With Atrial Fibrillation
Michael D. Ezekowitz et al.
CIRCULATION (2010)
Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate An Open-Label, Parallel-Group, Single-Centre Study
Joachim Stangier et al.
CLINICAL PHARMACOKINETICS (2010)
Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Current Clinical Evidence and Future Developments
Stephan H. Schirmer et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
Michael Rud Lassen et al.
LANCET (2010)
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial
Hans Chnstoph Diener et al.
LANCET NEUROLOGY (2010)
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Rupert Bauersachs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement.
Michael Rud Lassen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Assays for Measuring Rivaroxaban: Their Suitability and Limitations
Edelgard Lindhoff-Last et al.
THERAPEUTIC DRUG MONITORING (2010)
Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor
Meyer Michel Samama et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
Joanne van Ryn et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: A randomised controlled trial in healthy elderly adults
Meyer M. Samama et al.
THROMBOSIS RESEARCH (2010)
Warfarin Versus New Agents: Interpreting the Data
Jack Ansell
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2010)
Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regimen for Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
Jeffrey S. Ginsberg et al.
JOURNAL OF ARTHROPLASTY (2009)
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
Alexander G. G. Turpie et al.
LANCET (2009)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism.
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement
Michael Rud Lassen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Administration off label of recombinant factor-VIIa (rFVIIa) to patients with blunt or penetrating brain injury without coagulopathy
M. Zaaroor et al.
ACTA NEUROCHIRURGICA (2008)
Antithrombotic therapy for venous thromboembolic disease
Clive Kearon et al.
CHEST (2008)
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Ajay K. Kakkar et al.
LANCET (2008)
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
Bengt I. Eriksson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
Michael R. Lassen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
American society of clinical oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer
Gary H. Lyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement:: the RE-MODEL randomized trial
B. I. Eriksson et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement:: a randomised, double-blind, non-inferiority trial
Bengt I. Eriksson et al.
LANCET (2007)
Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux
T Lisman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2003)
Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers
NR Bijsterveld et al.
CIRCULATION (2002)
Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor
M Elg et al.
THROMBOSIS RESEARCH (2001)
Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits
M Elg et al.
THROMBOSIS RESEARCH (2001)
Share Paper
